Patents Assigned to Monash University
-
Publication number: 20230338552Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.Type: ApplicationFiled: June 26, 2023Publication date: October 26, 2023Applicants: PureTech LYT, Inc., Monash UniversityInventors: Daniel Kenneth Bonner, Rishab R. Shyam, Jamie Simpson, Christopher John Porter, Natalie Trevaskis, Tim Quach, Sifei Han, Luojuan Hu
-
Patent number: 11780915Abstract: The present disclosure is directed to human protease activated receptor 4 (PAR4) binding proteins (e.g. antibodies). In particular, anti-PAR4 binding proteins which are antagonists of human PAR4, as well as methods and uses thereof.Type: GrantFiled: September 11, 2018Date of Patent: October 10, 2023Assignee: MONASH UNIVERSITYInventors: Justin Hamilton, Mark Sleeman
-
Patent number: 11752116Abstract: This invention relates to methods of treating or preventing viral infections caused by flaviviruses, such as dengue virus, yellow fever virus, West Nile virus or Japanese encephalitis virus or infections caused by Chikungunya virus (CHIKV). The methods involve the administration of retinoic acid analogues to subjects who have, are suspected of having a flavivirus infection or infection with CHIKV, or to those who are at risk of becoming infected with a flavivirus or becoming infected with CHIKV.Type: GrantFiled: April 19, 2021Date of Patent: September 12, 2023Assignee: Monash UniversityInventors: Johanna Elisabeth Fraser, David Andrew Jans, Kylie Michelle Wagstaff
-
Publication number: 20230282944Abstract: A method of making a polyelectrolyte complex membrane separator for a Lithium-Sulfur battery to support lean electrolyte operation, comprising the steps of: forming polyelectrolyte complex nanoparticles by the addition of polyethylenimine (PEI) to tannic acid (TA); adding bovine serum albumin (BSA); purifying the nanoparticles; re-dispersing the nanoparticles in water to form a nanoparticle suspension; and dipcoating a polyolefin membrane in the nanoparticle suspension.Type: ApplicationFiled: July 23, 2021Publication date: September 7, 2023Applicant: MONASH UNIVERSITYInventors: Petar JOVANOVIC, Mahdokht SHAIBANI, Mainak MAJUMDER
-
Patent number: 11746396Abstract: An aluminium based alloy, and a method for production of components by additive manufacturing (AM) or other rapid solidification process with the alloy, is based on the alloy having a composition with from 2.01 wt % to 15.0 wt % manganese, from 0.3 wt % to 2.0 wt % scandium, with a balance apart from minor alloy elements and incidental impurities of aluminium.Type: GrantFiled: December 3, 2018Date of Patent: September 5, 2023Assignee: MONASH UNIVERSITYInventors: Paul Rometsch, Xinhua Wu, Qingbo Jia
-
Publication number: 20230272045Abstract: The present invention provides a fusion protein comprising interleukin-1 receptor antagonist (IL-1Ra) and an extracellular matrix (ECM) binding peptide which specifically binds to one or more or all extracellular matrix proteins selected from the group consisting of fibrinogen, fibronectin, vitronectin, tenascin C and heparan sulfate and use of the fusion protein to treat conditions in which administration of IL-1Ra is beneficial or in which IL-1R1 signalling needs to be dampened, to enhance tissue regeneration, particularly bone regeneration and/or wound repair or for treating wounds, burns and muscle, cartilage, tendon and bone disorders, to enhance the regenerative activity of growth factor administration or to reduce inflammation or desensitisation of a cell to growth factor stimulation.Type: ApplicationFiled: June 11, 2021Publication date: August 31, 2023Applicant: MONASH UNIVERSITYInventors: Mikaƫl MARTINO, Ziad JULIER
-
Patent number: 11738087Abstract: The present invention relates to compounds and their uses, in particular, compounds in the form of prodrugs that pro mote transport of a pharmaceutical agent to the lymphatic system and subsequently enhance release of the parent drug.Type: GrantFiled: September 8, 2016Date of Patent: August 29, 2023Assignee: Monash UniversityInventors: Chris Porter, Jamie Simpson, Natalie Trevaskis, Tim Quach, Sifei Han, Luojuan Hu
-
Publication number: 20230233590Abstract: The present disclosure generally relates to a method for reducing the toxicity of inhaled polymyxins as a therapeutic agent comprising the step of co-administration of an aminoglycoside; a method for improving the aerosolization of an aminoglycoside comprising the step of combination formulation with a polymyxin; and a process for manufacturing a dry powder composition comprising a polymyxin and aminoglycoside. Pharmaceutical compositions and methods of treatment for lung infections are within the scope of this invention.Type: ApplicationFiled: May 3, 2021Publication date: July 27, 2023Applicants: Purdue Research Foundation, Monash UniversityInventors: Qi Zhou, Maizbha Uddin Ahmed, Jian Li, Mohammad Abul Kalam Azad
-
Publication number: 20230227580Abstract: The invention also relates to antigen binding proteins and related fragments thereof for binding Von Willebrand factor (VWF) and uses thereof. In one aspect, the present invention provides an antigen binding protein comprising an antigen binding domain that binds to or specifically binds to Von Willebrand factor (VWF) under shear gradient conditions. Preferably, the antigen binding protein comprises an antigen binding domain that does not bind to VWF under constant shear conditions.Type: ApplicationFiled: June 25, 2021Publication date: July 20, 2023Applicants: MONASH UNIVERSITY, BAKER HEART AND DIABETES INSTITUTEInventors: Christoph HAGEMEYER, Erik WESTEIN, Thomas HOEFER, Robert ANDREWS, Elizabeth GARDINER
-
Patent number: 11702457Abstract: An agent capable of promoting proliferation and differentiation of granulosa cells is disclosed which comprises a growth and differentiation factor-9 (GDF9) protein comprising a modified GDF9 polypeptide monomer which includes at least one amino acid substitution that enhances binding to and/or activation of activin-like kinase 4 and/or 5 receptor (ALK4/5). The agent is preferably provided in a mature dimeric form (eg comprising two monomers of the same modified GDF9 polypeptide monomer) and/or in a pro/mature complex form. The agent may be suitable for, inter alia, promoting oocyte maturation in vitro for use in assisted reproductive technologies.Type: GrantFiled: May 9, 2019Date of Patent: July 18, 2023Assignee: Monash UniversityInventors: Craig Anthony Harrison, Kelly Louise Walton
-
Patent number: 11690938Abstract: A surgical system for use in establishing and maintaining an opening to an anatomical space of a body, the system comprising an obturator assembly having a cutting portion at a distal end and a cannula, the cannula being detachably coupled to the cutting portion and deployable into the anatomical space of a patient, the cannula comprises a locking portion, and a lengthwise extendable body; a valve assembly comprising a passage for receiving the cannula, a first end for coupling to a fluid extraction device and a second end for placement external and adjacent the anatomical space; a base comprising a plate for placement on a patient external and adjacent the anatomical space, the plate has an aperture configured for receiving the obturator assembly and coupling means located about the aperture for coupling with the valve assembly; and wherein, in use, the locking portion of the cannula is configured to be retained in the valve assembly with the extendable body extended into the anatomical space to facilitate aType: GrantFiled: November 22, 2017Date of Patent: July 4, 2023Assignees: Alfred Health, Monash UniversityInventors: Mark Fitzgerald, Peter Finnegan, Wing Chiu, Nayeem Chowdhury, Nabil Chowdhury
-
Patent number: 11674143Abstract: An isolated or purified AON for modifying pre-mRNA splicing in the Receptor for Advanced Glycation End-products (RAGE) to modulate splicing of the RAGE gene transcript or part thereof is provided.Type: GrantFiled: September 7, 2022Date of Patent: June 13, 2023Assignees: MONASH UNIVERSITY, MURDOCH UNIVERSITYInventors: Stephen Wilton, Merlin Christopher Thomas, Carlos Rosado, Raelene Jane Pickering
-
Patent number: 11608345Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.Type: GrantFiled: December 19, 2018Date of Patent: March 21, 2023Assignees: PureTech LYT, Inc., Monash UniversityInventors: Daniel Kenneth Bonner, Sifei Han, Luojuan Hu, Ketki Karanam, Christopher John Porter, Tim Quach, Rishab R. Shyam, Jamie Simpson, Natalie Trevaskis
-
Publication number: 20230015481Abstract: An isolated or purified AON for modifying pre-mRNA splicing in the Receptor for Advanced Glycation End-products (RAGE) to modulate splicing of the RAGE gene transcript or part thereof is provided.Type: ApplicationFiled: September 7, 2022Publication date: January 19, 2023Applicants: MONASH UNIVERSITY, MURDOCH UNIVERSITYInventors: Stephen WILTON, Merlin Christopher THOMAS, Carlos ROSADO, Raelene Jane PICKERING
-
Patent number: 11557788Abstract: Electrolytes and electrochemical cells include a novel ionic liquid having a quaternary cation and a boron cluster anion. In some versions, the boron cluster anion will be a functionalized or unfunctionalized icosahedral boranyl or carboranyl anion. Electrochemical cells have an electrolyte including the ionic liquid. In some versions, the ionic liquid is used as a solvent to dissolve an ionic shuttle salt for transport of active material, with an optional co-solvent. Methods to synthesize the ionic liquid include contacting a boron cluster salt with a quaternary salt to form the ionic liquid by a metathesis reaction.Type: GrantFiled: May 13, 2020Date of Patent: January 17, 2023Assignees: Toyota Motor Engineering & Manufacturing North America, Inc., Monash UniversityInventors: Rana Mohtadi, Oscar Tutusaus, Douglas R. MacFarlane, Mega Kar
-
Publication number: 20220395513Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.Type: ApplicationFiled: August 4, 2022Publication date: December 15, 2022Applicants: PureTech LYT, Inc., Monash UniversityInventors: Daniel Kenneth Bonner, Rishab R. Shyam, Jamie Simpson, Christopher John Porter, Natalie Trevaskis, Tim Quach, Sifei Han, Luojuan Hu
-
Patent number: 11471874Abstract: Disclosed herein is an ion selective separation membrane including: a metal organic framework layer formed on, in, and/or around a substrate, the metal organic framework having a crystal structure that includes a first surface and a second surface and includes ion transport channels formed between respective pore windows in the first surface and the second surface; first and second electrodes to apply a potential difference across the membrane; wherein the respective pore windows have a pore size that is less than the hydrated diameter of the ion for which the ion selective separation membrane is selective.Type: GrantFiled: December 14, 2018Date of Patent: October 18, 2022Assignees: Monash University, Commonwealth Scientific and Industrial Research Oganisation, Board of Regents, The University of Texas SystemInventors: Huanting Wang, Huacheng Zhang, Xingya Li, Jun Lu, Benny Freeman, Anita Joyce Hill
-
Patent number: 11446393Abstract: Non-viral nucleic acid delivery agents and methods for the delivery or transfer of nucleic acid molecules to target cells are disclosed. The agents comprise a complex of a nucleic acid cargo for delivery, one or more lipopeptide compound, and one or more polymeric charge-neutralising agent, and the complex is in the form of a particle with substantially neutral or negative surface charge. The agents and methods may be useful in a variety of applications such as therapies (including gene therapies and nucleic acid vaccinations) for diseases and medical disorders.Type: GrantFiled: June 8, 2018Date of Patent: September 20, 2022Assignee: Monash UniversityInventors: Colin William Pouton, Kha Tu Joan Ho, Paul James White, Catherine Thoa Bui, Nabila Akhtar, Hareth Ali Al-Wassiti
-
Patent number: 11441148Abstract: An isolated or purified AON for modifying pre-mRNA splicing in the Receptor for Advanced Glycation End-products (RAGE) to modulate splicing of the RAGE gene transcript or part thereof is provided.Type: GrantFiled: August 25, 2021Date of Patent: September 13, 2022Assignees: MONASH UNIVERSITY, MURDOCH UNIVERSITYInventors: Stephen Wilton, Merlin Christopher Thomas, Carlos Rosado, Raelene Jane Pickering
-
Patent number: D1003426Type: GrantFiled: January 7, 2021Date of Patent: October 31, 2023Assignee: MONASH UNIVERSITYInventors: Richard Morfuni, Daphne Flynn, Rowan Page, Mark C. Armstrong, Tuncay Alan, Jason Brenker